e6vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of
May 2008
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Oncolytics
Biotech Inc.
(Registrant) |
|
|
|
|
|
|
|
Date: May 16, 2008 |
|
By: |
|
/s/ Brad Thompson
Brad Thompson
President and CEO |
|
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Collaborators to Present
Phase II Sarcoma Trial Results at ASCO Annual Meeting
CALGARY,
AB, May 16, 2008 Oncolytics Biotech Inc.
(TSX: ONC, NASDAQ: ONCY) announced today that an abstract covering interim results of a Phase II study of intravenous
REOLYSIN® in patients with sarcomas metastatic to the lung is available on the American
Society of Clinical Oncology (ASCO) website at www.asco.org and on the Oncolytics website at
www.oncolyticsbiotech.com. The abstract is entitled A Phase II Study of Intravenous REOLYSIN
(Wild-type reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to
the Lung. The abstract discusses results of this study up to early January, 2008.
Dr. Monica Mita, Principal Investigator at the Cancer Therapy and Research Center at the University
of Texas Health Science Center (CTRC at UTHSC), San Antonio, Texas and her team are scheduled to
deliver a poster presentation providing updated information on the trial at the 44th
ASCO annual meeting, which runs from May 30 to June 3, 2008 in Chicago, Illinois.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication
of the abstract and materials presented on the ASCO website and at this meeting with respect to
REOLYSIN®, the Companys expectations related to the results of trials investigating
delivery of REOLYSIN
®, and the Companys belief
as to the potential of REOLYSIN
®
as a cancer therapeutic, involve known and unknown risks and uncertainties,
which could cause the Companys actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the efficacy of
REOLYSIN®
as a cancer treatment, the success and timely completion of clinical studies
and trials, the Companys ability to successfully commercialize REOLYSIN®, uncertainties
related to the research and development of pharmaceuticals, uncertainties related to the regulatory
process and general changes to the economic environment. Investors should consult the Companys
quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group
|
|
The Investor Relations Group |
Cathy Ward
|
|
Nick Hurst
|
|
Erika Moran |
210, 1167 Kensington Cr NW
|
|
325, 300 5th Ave. SW
|
|
11 Stone St, 3rd Floor |
Calgary, Alberta T2N 1X7
|
|
Calgary, Alberta, T2P 3C4
|
|
New York, NY 10004 |
Tel: 403.670.7377
|
|
Tel: 403.538.4845
|
|
Tel: 212.825.3210 |
Fax: 403.283.0858
|
|
Fax: 403.237.6916
|
|
Fax: 212.825.3229 |
cathy.ward@oncolytics.ca
|
|
nhurst@equicomgroup.com
|
|
emoran@investorrelationsgroup.com |
-30-